Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
three
months ended in Jun. 2026,
Elanco Animal Health paid$1 Mil more to buy back shares than it received from issuing new shares.
It spent$73 Mil paying down its debt.
It paid$0 Mil more to buy back preferred shares than it received from issuing preferred shares.
It received$0 Mil from paying cash dividends to shareholders.
It received$0 Mil on other financial activities.
In all, Elanco Animal Healthspent$74 Mil on financial activities for the
three
months ended in Jun. 2026.
Elanco Animal Health (NYSE:ELAN) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
Elanco Animal Health's issuance of stock for the
three
months ended in Jun. 2026 was $0 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
Elanco Animal Health's repurchase of stock for the
three
months ended in Jun. 2026 was $-1 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
Elanco Animal Health's net issuance of debt for the
three
months ended in Jun. 2026 was $-73 Mil.
Elanco Animal Health spent$73 Mil paying down its debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
Elanco Animal Health's net issuance of preferred for the
three
months ended in Jun. 2026 was $0 Mil.
Elanco Animal Health paid$0 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Elanco Animal Health's cash flow for dividends for the
three
months ended in Jun. 2026 was $0 Mil.
Elanco Animal Health received$0 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
Elanco Animal Health's other financing for the
three
months ended in Jun. 2026 was $0 Mil.
Elanco Animal Health received$0 Mil on other financial activities.
Elanco Animal Health Cash Flow from Financing Related Terms
Elanco Animal Health Cash Flow from Financing Historical Data
* Premium members only.
The historical data trend for Elanco Animal Health's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Elanco Animal Health Cash Flow from Financing Chart
Elanco Animal Health Cash Flow from Financing Calculation
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
Elanco Animal Health's Cash from Financing for the fiscal year that ended in Dec. 2025 is calculated as:
Cash Flow from Financing for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-310 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Financing of $-310 Mil mean?
Elanco Animal Health (ELAN) has a Cash Flow from Financing of $-310 Mil as of Jun. 2026. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Elanco Animal Health and its competitors.
Is Elanco Animal Health's Cash Flow from Financing too high?
Elanco Animal Health's current Cash Flow from Financing is $-310 Mil. Overall, Elanco Animal Health has a GF Score™ of 74/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Elanco Animal Health's Cash Flow from Financing compare to ALKS and LQDA?
Elanco Animal Health's Cash Flow from Financing of $-310 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Drug Manufacturers company?
A good Cash Flow from Financing depends on the Drug Manufacturers industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Elanco Animal Health and its competitors. Elanco Animal Health's current Cash Flow from Financing is $-310 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elanco Animal Health stock overvalued right now?
Based on GuruFocus' analysis, Elanco Animal Health (ELAN) is currently considered Significantly Overvalued. The stock's GF Value™ is $16.64, compared to a current price of $22.73 — trading 36.6% above its estimated fair value. The current Cash Flow from Financing is $-310 Mil. Elanco Animal Health's overall GF Score™ is 74/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For Elanco Animal Health (ELAN), the current Cash Flow from Financing is $-310 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Elanco Animal Health (ELAN) Overvalued in 2026?
Based on GuruFocus' analysis, Elanco Animal Health stock appears to be overvalued.
The current stock price of $22.73 is trading 36.6% above its estimated GF Value™ of $16.64.
GuruFocus considers Elanco Animal Health to be Significantly Overvalued.
Key valuation signals for ELAN:
Cash Flow from Financing: $-310 Mil
GF Value™: $16.64 vs. price of $22.73 (36.6% above fair value)
No single metric tells the full story. See the ELAN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, poultry, and swine production.
74GF Score
Get the complete analysis for ELAN
Cash Flow from Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ELAN has been successfully added to your 
